SPTBN5 Antibody

What is SPTBN5 and what are its key characteristics?

SPTBN5 (Spectrin beta, non-erythrocytic 5) is a member of the spectrin family of cytoskeletal proteins. In humans, the canonical protein has a length of 3674 amino acid residues and a mass of 416.8 kDa . Its subcellular localization is primarily cytoplasmic, with notable expression in the cerebellum and retina . SPTBN5 contains multiple functional domains including:

• Actin-binding domain

• Membrane-association domain-1

• Self-association domain

• C-terminal pleckstrin homology domain

Based on these structural features, SPTBN5 likely forms heterodimers and oligomers with alpha-spectrin and interacts directly with cellular membranes . Recent studies have implicated SPTBN5 variants in neurodevelopmental disorders including intellectual disability and autism spectrum disorders .

What applications are SPTBN5 antibodies validated for?

SPTBN5 antibodies have been validated for multiple research applications, with varying protocols and optimization requirements:

The choice of application should be guided by the specific experimental question and available tissue or cell samples .

How should I properly validate a new SPTBN5 antibody?

Proper validation of SPTBN5 antibodies involves multiple steps:

• Western blot confirmation: Verify the antibody detects a protein of expected molecular weight (417 kDa for human SPTBN5, or ~92 kDa for specific mouse Spnb5 protein)

• Positive control tissues: Use cerebellum and retina samples which express high levels of SPTBN5

• Negative controls: Include tissues with minimal SPTBN5 expression or use blocking peptides

• Cross-reactivity assessment: Determine if the antibody cross-reacts with other spectrin family members or between species (some antibodies may cross-react between mouse and human)

• Antibody specificity verification: Consider using genetic knockdown models or comparing results with alternative antibodies targeting different epitopes

Rigorous validation ensures reliable experimental results and minimizes false positives or negatives in downstream applications.

What are the optimal protocols for SPTBN5 immunodetection in tissue sections?

For optimal SPTBN5 immunodetection in tissue sections, the following protocol is recommended based on published literature:

• Tissue preparation:

  • Use paraffin-embedded sections (2-5 μm thickness)

  • De-paraffinize in xylene

  • Hydrate through graded ethanol and PBS

• Antigen retrieval (critical step):

  • Pressure-cook at >100°C in 0.1 M citrate buffer, pH 6.0

  • This step is essential for exposing SPTBN5 epitopes masked during fixation

• Blocking and antibody incubation:

  • Block with 2% BSA for 30 min at room temperature

  • Dilute primary antibody in 2% BSA/0.1% saponin PBS

  • Incubate with primary antibody overnight at 4°C

• Detection methods:

  • For immunofluorescence: Use secondary antibodies conjugated to Alexa dyes (1:1,000 dilution)

  • For immunoperoxidase: Use polymer peroxidase reagents followed by DAB development and hematoxylin counterstaining

This protocol has been successfully employed in studies examining SPTBN5 localization in brain tissues, particularly in the cerebellum .

How do I select the appropriate SPTBN5 antibody for my specific research needs?

Selection criteria for SPTBN5 antibodies should include:

• Target species compatibility: Verify the antibody recognizes SPTBN5 from your species of interest. Most commercial antibodies target either human or mouse SPTBN5, with some showing cross-reactivity

• Application validation: Confirm the antibody is validated for your intended application (WB, IHC, ICC, ELISA) as performance can vary significantly between applications

• Epitope consideration:

  • For full-length protein detection: Antibodies targeting conserved regions

  • For specific domain studies: Antibodies targeting particular domains (e.g., actin-binding domain)

  • For variant studies: Antibodies that can distinguish wild-type from mutant forms

• Format selection: Choose between:

  • Unconjugated antibodies (most versatile)

  • Directly conjugated to fluorophores (Alexa Fluor 488, 594, 647, etc.) for direct detection

  • Biotin-conjugated for signal amplification

• Scientific evidence: Review citation records and validation data from manufacturers to assess reliability

The table below summarizes some available SPTBN5 antibody formats:

How can I troubleshoot weak or non-specific SPTBN5 antibody signals?

Common issues with SPTBN5 antibody detection and their solutions:

• Weak signal:

  • Increase antibody concentration (try 2-5× higher concentration)

  • Extend incubation time (up to 48 hours at 4°C)

  • Optimize antigen retrieval (try different buffers or longer retrieval times)

  • Use signal amplification methods (tyramide signal amplification or polymer detection systems)

  • Ensure proper sample preparation (protein extraction methods for WB)

• High background/non-specific binding:

  • Increase blocking time or concentration (try 5% BSA or 10% normal serum)

  • Add 0.1-0.3% Triton X-100 to reduce non-specific binding

  • Include additional washing steps

  • Use more dilute antibody concentration

  • Pre-adsorb antibody with tissues lacking SPTBN5 expression

• Multiple bands in Western blot:

  • Verify if bands represent degradation products or isoforms

  • Include protease inhibitors during sample preparation

  • Use freshly prepared samples

  • Run gradient gels for better separation of high molecular weight proteins

• No signal in expected tissues:

  • Confirm SPTBN5 expression in your sample (by RT-PCR)

  • Try alternative fixation methods

  • Verify antibody reactivity to your species of interest

  • Consider epitope masking issues

How can SPTBN5 antibodies be used to study neurodevelopmental disorders?

Recent research has associated SPTBN5 mutations with intellectual disability, developmental delay, seizures, and autistic behavior . SPTBN5 antibodies can be valuable tools in studying these conditions:

• Mutation impact analysis:

  • Compare SPTBN5 expression and localization in cellular models expressing wild-type versus mutant variants

  • Four specific variants have been identified that cause neurodevelopmental phenotypes:

    • c.266A>C; p.His89Pro

    • c.9784G>A; p.Glu3262Lys

    • c.933C>G; p.Tyr311*

    • c.8809A>T; p.Asn2937Tyr

• Structural and functional studies:

  • Examine how mutations affect SPTBN5's interaction with cytoskeletal components

  • Investigate changes in protein stability, localization, or post-translational modifications

  • Study effects on neuronal morphology, connectivity, and function

• Comparative tissue analysis:

  • Analyze SPTBN5 expression patterns in cerebellum and retina in normal versus affected individuals

  • Examine co-localization with other proteins implicated in neurodevelopmental disorders

  • Study developmental expression patterns during critical brain development periods

This research may provide insights into the molecular mechanisms underlying SPTBN5-associated neurodevelopmental disorders and potentially identify therapeutic targets.

How can SPTBN5 antibodies be optimized for multiplex immunofluorescence studies?

Multiplex immunofluorescence with SPTBN5 antibodies requires careful optimization:

• Primary antibody selection:

  • Choose antibodies from different host species (e.g., rabbit anti-SPTBN5 with mouse antibodies against other targets)

  • Verify antibody compatibility in multiplexing (some antibodies may compete for binding sites)

• Fluorophore strategy:

  • For directly conjugated SPTBN5 antibodies, select from available options (Alexa Fluor 488, 594, 647, 680, 750) based on your microscopy setup

  • Choose fluorophores with minimal spectral overlap to reduce bleed-through

  • Consider brightness requirements (SPTBN5 may require brighter fluorophores if expression is low)

• Sequential staining approach:

  • When using antibodies from the same species, employ sequential staining with intermediate blocking steps

  • Consider tyramide signal amplification for weak signals

  • Use spectral imaging and unmixing to separate overlapping signals

• Controls for multiplex experiments:

  • Single-stain controls to assess bleed-through

  • Isotype controls to evaluate non-specific binding

  • Absorption controls using blocking peptides

  • Tissue controls with known expression patterns

This approach allows simultaneous visualization of SPTBN5 alongside other proteins of interest, such as neuronal markers or other cytoskeletal components, providing insights into potential functional relationships.

What considerations are important when studying SPTBN5 in different brain regions?

When investigating SPTBN5 expression and function across brain regions, several important considerations should be addressed:

• Region-specific optimization:

  • Cerebellum: SPTBN5 shows high expression in cerebellum, particularly in Purkinje cells

    • Use thin sections (2-5 μm) for detailed visualization of cerebellar layers

    • Consider co-staining with Purkinje cell markers

    • Compare SPTBN5 expression across different cerebellar regions

  • Retina: Another site of high SPTBN5 expression

    • Use fresh-frozen sections to preserve antigenicity

    • Consider co-staining with retinal cell type-specific markers

    • Use confocal microscopy to visualize the complex layered structure

• Developmental considerations:

  • SPTBN5 expression changes during development

  • Time-course studies require age-matched samples

  • Consider embryonic, postnatal, and adult time points

• Pathological contexts:

  • Compare SPTBN5 expression in normal versus diseased tissues

  • Look for changes in localization, not just expression level

  • Consider both acute and chronic disease models

• Technical considerations:

  • Brain tissue often requires specialized fixation and processing

  • Antigen retrieval is critical for many brain regions

  • Lipid-rich regions may require special permeabilization protocols

  • Autofluorescence may require quenching techniques

Understanding region-specific SPTBN5 expression patterns may provide insights into the selective vulnerability of certain brain regions in SPTBN5-associated disorders.

How do SPTBN5 antibodies compare with other spectrin family antibodies in neurological research?

Comparing SPTBN5 antibodies with other spectrin family antibodies reveals important distinctions relevant to neurological research:

• Specificity challenges:

  • The spectrin family includes numerous members (SPTAN1, SPTBN1, SPTBN2, SPTBN4, SPTBN5)

  • Antibody cross-reactivity between family members is a common issue

  • Careful validation is required to ensure specificity to SPTBN5

• Comparative expression patterns:

  • Different spectrin family members show distinct expression patterns in the nervous system:

    • βI spectrin: broadly expressed in neurons

    • βII spectrin: widespread expression

    • βIII spectrin: high in Purkinje cells

    • βIV spectrin: nodes of Ranvier, axon initial segments

    • βV spectrin (SPTBN5): cerebellum and retina

  • Understanding these patterns helps interpret experimental results

• Methodological differences:

  • Some spectrin proteins require specific fixation methods

  • Molecular weights vary considerably (SPTBN5 is particularly large at 417 kDa)

  • Some spectrin antibodies perform better in certain applications

Understanding these differences is essential when studying multiple spectrin family members simultaneously or when interpreting results in the context of neurological disorders associated with different spectrin proteins.